Resultados de la búsqueda
Gonzalez-Lopez E, Maurer MS, Garcia-Pavia P. Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. Eur Heart J (2025) 46:999-1013
Van Linthout S, Stellos K, Giacca M, Bertero E, Cannata A, Carrier L, Garcia-Pavia P, Ghigo A, González A, Haugaa KH, Imazio M, Lopes LR, Most P, Pollesello P, Schunkert H, Streckfuss-Bömeke K, Thum T, Tocchetti CG, Tschöpe C, van der Meer P, van Rooij E, Metra M, Rosano GMC, Heymans S. State of the art and perspectives of gene therapy in heart failure. A scientific statement of the Heart Failure Association of the ESC, the ESC Council on Cardiovascular Genomics and the ESC Working Group on Myocardial & Pericardial Diseases. Eur J Heart Fail (2025) 27:5-25
Garcia-Pavia P, Bilen O, Burroughs M, Costabel JP, de Barros Correia E, Dybro AM, Elliott P, Lakdawala NK, Mann A, Nair A, Nassif ME, Poulsen SH, Reant P, Schulze PC, Wang A, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn R, Wohltman A, Fifer MA; MAPLE-HCM Study Investigators. Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics. JACC Heart Fail (2025) 13:346-357
Desai MY, Nissen SE, Abraham T, Olivotto I, Garcia-Pavia P, Lopes RD, Verheyen N, Wever-Pinzon O, Wolski K, Jaber W, Mitchell L, Davey D, Myers J, Rano T, Bhatia V, Zhong Y, Carter-Bonanza S, Florea V, Aronson R, Owens AT; ODYSSEY-HCM Investigators. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM. JACC Heart Fail (2025) 13:358-370
Casas G, Ródenas-Alesina E, Limeres J, Badia-Molins C, Larrañaga-Moreira JM, Mirelis JG, Navarrete-Navarro J, Martín-Jiménez J, Alcalá-López JE, González-Carrillo J, Teis A, Soler-Fernández R, Teixidó-Turà G, Gutiérrez-García L, Fernández-Álvarez P, Muñoz-Cabello P, Barrabés JA, Tirón C, Palomino-Doza J, García-Pinilla JM, Bayés-Genís A, Ripoll-Vera T, Jiménez-Jáimez J, Villacorta E, Gimeno-Blanes JR, Zorio E, García-Pavía P, Barriales-Villa R, Guala A, Petersen SE, Ferreira-González I, Rodríguez-Palomares JF. Left ventricular ejection fraction decline and cardiovascular events in suspected cardiomyopathy with excessive trabeculation: toward precision medicine. Rev Esp Cardiol (2025) S1885-5857:00044-1
Cabrera-Romero E, Serrao-Faria LA, Mora-Ayestarán N, Peiró-Aventín B, Espinoza A, de Castro D, Cobo-Marcos M, Domínguez F, González-López E, Garcia-Pavia P. Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy. Amyloid (2025) 32:87-89
Suhr OB, Grogan M, Silva AMD, Karam C, Garcia-Pavia P, Drachman B, Zago W, Tripuraneni R, Kinney GG. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. Amyloid (2025) 32:14-21
Filamin C Registry Consortium; Gigli M, Stolfo D, Barbati G, Graw S, Chen SN, Merlo M, Medo K, Gregorio C, Dal Ferro M, Paldino A, Perotto M, Peter van Tintelen J, Te Riele ASJM, Baas AF, Wilde AM, Amin AS, Houweling AC, Elliott P, Cannie D, Michels M, Schoonvelde SAC, Prasad S, Tayal PU, Yazdani M, Morris-Rosendahl D, Garcia-Pavia P, Cabrera-Romero E, Bauce B, Pilichou K, Fatkin D, Johnson R, Judge DP, Foil KL, Heymans S, Verdonschot JAJ, Stroeks SLVM, Lakdawala NK, Anisha P, O'Neill M, Shoemaker MB, Roden DM, Calkins H, James CA, Murray B, Parikh VN, Ashley EA, Reuter C, Imazio M, Canepa M, Ameri P, Song J, Sinagra G, Taylor MRG, Mestroni L. Arrhythmic Risk Stratification of Carriers of Filamin C Truncating Variants. JAMA Cardiol (2025) 10:359-369
Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, Düngen HD, Garcia-Pavia P, Hagège AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham TP; SEQUOIA-HCM Investigators. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med (2024) 390:1849-1861.
Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, Damy T, Garcia-Pavia P, Taubel J, Solomon SD, Sheikh FH, Tahara N, González-Costello J, Tsujita K, Morbach C, Pozsonyi Z, Petrie MC, Delgado D, Van der Meer P, Jabbour A, Bondue A, Kim D, Azevedo O, Hvitfeldt Poulsen S, Yilmaz A, Jankowska EA, Algalarrondo V, Slugg A, Garg PP, Boyle KL, Yureneva E, Silliman N, Yang L, Chen J, Eraly SA, Vest J, Maurer MS; HELIOS-B Trial Investigators. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med (2024) 392:33-44.
